TABLE 1.
Characteristics of COVID‐19 hematological patients enrolled in the study
| Number of patients, n (%) | 88 (100) |
| Age at the time of COVID‐19 diagnosis, years, median; mean (range) | 63; 58 (19–84) |
| Sex, male, n (%) | 48 (55) |
| Comorbidities, n (%) | |
| Hypertension | 32 (36) |
| Diabetes mellitus | 18 (21) |
| Dyslipidemia | 14 (16) |
| Coronary heart disease | 11 (13) |
| Smoking | 8/79 (10) |
| Allergy | 38/82 (46) |
| Pulmonary disease | 7 (8) |
| Obesity | 6 (7) |
| Other | 32 (36) |
| None | 21 (24) |
| Unknown | 4 (5) |
| Underlying disease at baseline, n (%) | |
| Lymphoma | 30 (34) |
| Acute leukemia | 17 (19) |
| Multiple myeloma | 17 (19) |
| Chronic lymphocytic leukemia | 12 (14) |
| Myeloproliferative neoplasias | 4 (5) |
| Chronic myeloid leukemia | 2 (2) |
| Myelodysplastic syndrome | 2 (2) |
| Other hematological diseases | 4 (5) |
| Number of days between diagnosis of hematological disease and COVID‐19, median; mean (range) | 406; 1462 (5–16,367) |
| Last hematological therapy 2 years prior to COVID‐19, n (%) | |
| Anti‐CD20 monoclonal antibody (rituximab in all cases) | 28 (32) |
| Another chemotherapy | 27 (31) |
| Autologous SCT | 8 (9) |
| Allogeneic SCT | 6 (7) |
| Corticosteroids | 4 (5) |
| None | 14 (16) |
| Number of days between last hematological therapy and COVID‐19 diagnosis, median; mean (range) | 19; 74 (0–721) |
| SARS‐CoV‐2 vaccination before COVID‐19 diagnosis, n (%) | |
| Total number of vaccinated patients | 29/81 (36) |
| Number of patients only after 1st dosage of vaccination | 25 (31) |
| Number of days between 1st dosage of vaccination and COVID‐19 diagnosis, median; mean (range) | 15; 19 (6–53) |
| Number of patients after 2nd dosage of vaccination | 4 (5) |
| Number of days between 2nd dosage of vaccination and COVID‐19 diagnosis, median; mean (range) | 22; 33 (5–83) |
| COVID‐19 second episode, n (%) | 12/82 (15) |
| Type of anti‐SARS‐CoV‐2 monoclonal neutralizing antibody, n (%) | |
| Bamlanivimab | 63 (72) |
| Casirivimab/imdevimab | 25 (28) |
| Number of days between COVID‐19 diagnosis and NmAb administration, median; mean (range) | 1; 1.4 (0–6) |
Abbreviations: COVID‐19, coronavirus disease 2019; NmAbs, neutralizing monoclonal antibodies; SARS‐CoV‐2, severe acute respiratory syndrome‐related coronavirus‐2; SCT, stem cell transplantation.